|
市場調査レポート
商品コード
234470
抗体関連の各種提携契約 - 契約条件・合意内容：資本取引の動向・企業・財務状況Antibody Collaboration and Licensing Deals 2016-2023 |
||||||
|
|
|||||||
| 抗体関連の各種提携契約 - 契約条件・合意内容：資本取引の動向・企業・財務状況 |
|
出版日: 2023年11月01日
発行: Current Partnering
ページ情報: 英文 950+ Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 目次
当レポートでは、抗体関連の各種資本取引／事業提携の契約締結について分析し、近年における各種契約の締結動向や、大規模契約および大手医薬品事業者による契約の概要、契約種類別／治験段階別／技術別／治療内容別の契約一覧、といった情報を取りまとめてお届けいたします。
エグゼクティブサマリー
第1章 イントロダクション
第2章 抗体関連の各種取引動向
- イントロダクション
- 近年の抗体関連の事業提携件数
- 最も活動的だった、抗体関連の取引主体
- 抗体関連の事業提携：取引の種類別
- 抗体関連の事業提携：治療領域別
- 抗体関連の事業提携：取引条件
- 取引総額 (headline values)
- 前払い金
- マイルストーン払い
- ロイヤルティ率
第3章 抗体関連の主要な取引
- イントロダクション
- 代表的な資本取引 - 取引金額
第4章 抗体関連の最も活動的な取引主体
- イントロダクション
- 抗体関連の最も活動的な取引主体
- 最も活動的な取引主体：企業プロファイル
第5章 抗体関連の契約締結の一覧
- イントロダクション
- 締結された契約の一覧 (ディレクトリ)
第6章 抗体関連の取引動向：技術の種類別
第7章 抗体関連のリソースセンター
- 抗体関連のオンライン・データベース
- 抗体関連のイベント／会議
- 抗体関連の参考文献
付録
- 付録 (1) - 抗体関連の資本取引：企業別 (ABC順)
- 付録 (2) - 抗体関連の資本取引：治験段階別
- 創薬
- 前臨床
- 第I相
- 第II相
- 第III相
- 申請登録
- 上市済み
- 剤型
- 付録 (3) - 抗体関連の資本取引：取引の種類別
- 資産購入
- 権利譲渡
- 大手医薬品企業のアウトライセンシング
- 共同開発
- 共同研究開発 (R&D)
- 共同マーケティング
- 共同プロモーション
- CRADA (共同研究開発契約)
- クロスライセンシング
- 開発
- 流通
- 株式購入
- 評価
- 譲与
- 合弁事業 (ジョイントベンチャー)
- ライセンシング
- ローン
- 製造
- マーケティング
- 材料転移
- オプション
- プロモーション
- 研究
- 和解調停
- スピンアウト
- 二次ライセンス
- 供給
- 技術移転
- 契約解除
- 付録 (4) - 抗体関連の資本取引：治療領域別
- 心血管
- 中枢神経系
- 歯科
- 皮膚科
- 消化器
- 血液
- 入院治療
- 免疫
- 感染症
- 代謝
- 筋骨格系疾患
- 産科
- 腫瘍 (癌)
- 眼科
- 希少疾患
- 小児科
- 精神科
- 呼吸器
- 付録 (5) - 資本取引の種類：定義
Wildwood Venturesについて
Description
Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibody deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of antibody deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 1812 antibody deals announced since 2016 including financial terms where available including links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of antibody dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in antibody dealmaking since 2016.
Chapter 3 provides an overview of the leading antibody deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibody technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in antibody deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse antibody collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
- Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibody trends and structure of deals entered into by leading biopharma companies worldwide.
Antibody Collaboration and Licensing Deals includes:
- Trends in antibody dealmaking in the biopharma industry
- Directory of antibody deal records covering pharmaceutical and biotechnology
- The leading antibody deals by value
- Most active antibody licensing dealmakers
- Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse antibody collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in antibody dealmaking
- 2.1. Introduction
- 2.2. Antibody deals over the years
- 2.3. Most active antibody dealmakers
- 2.4. Antibody deals by deal type
- 2.5. Antibody deals by therapy area
- 2.6. Antibody deals by industry sector
- 2.7. Deal terms for antibody deals
- 2.7.1 Antibody deals headline values
- 2.7.2 Antibody deal upfront payments
- 2.7.3 Antibody deal milestone payments
- 2.7.4 Antibody royalty rates
Chapter 3 - Leading antibody deals
- 3.1. Introduction
- 3.2. Top antibody deals by value
Chapter 4 - Most active antibody dealmakers
- 4.1. Introduction
- 4.2. Most active antibody dealmakers
- 4.3. Most active antibody deals company profiles
Chapter 5 - Antibody contracts dealmaking directory
- 5.1. Introduction
- 5.2. Antibody contracts dealmaking directory
Chapter 6 - Antibody dealmaking by technology type
- Deal directory
- Deal directory - Antibody deals by company A-Z
- Deal directory - Antibody deals by deal type
- Deal directory - Antibody deals by therapy area
- Deal type definitions
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent report titles from Current Partnering
Table of figures
- Figure 1: Antibody deals since 2016
- Figure 2: Active antibody dealmaking activity - 2016 - 2023
- Figure 3: Antibody deals by deal type since 2016
- Figure 4: Antibody deals by therapy area since 2016
- Figure 5: Antibody deals by industry sector since 2016
- Figure 6: Antibody deals with a headline value
- Figure 7: Antibody deals with an upfront value
- Figure 8: Antibody deals with a milestone value
- Figure 9: Antibody deals with a royalty rate value
- Figure 10: Top antibody deals by value since 2016
- Figure 11: Most active antibody dealmakers 2016 - 2023
- Figure 12: Antibody deals by technology type since 2016
